Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28412816 | 0.81 | EGFR (0.71) | EGFRMKNK2 | |
| SCHEMBL2642168 | 0.77 | NPC1 (0.53) | EGFRMKNK2 | |
| SCHEMBL12275900 | 0.77 | EGFR (0.54) | EGFRMKNK2 | |
| SCHEMBL2621718 | 0.77 | EGFR (0.54) | EGFRMKNK2 | |
| SCHEMBL29439793 | 0.77 | EGFR (0.54) | EGFRMKNK2 | |
| SCHEMBL30127607 | 0.76 | EGFR (0.50) | EGFRMKNK2 | |
| SCHEMBL29444155 | 0.75 | EGFR (0.66) | EGFRMKNK2 | |
| SCHEMBL22590144 | 0.75 | EGFR (0.66) | EGFRMKNK2 | |
| SCHEMBL6836412 | 0.75 | EGFR (1.00) | EGFR | |
| SCHEMBL30125903 | 0.75 | EGFR (0.55) | EGFRMKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422298-B2 | Pyridopyrimidine derivatives and use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-20150158874-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | CMG PHARMACEUTICAL CO., LTD. | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158874-A1 | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF | PIK3CA, PIK3CD, PI4KA | EGFR 1900/4885MKNK2 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.